Retour aux projets

25758.1 PFLS-LS

Developing a therapeutic vaccination targeting pruritus in equine

Résumé

Developing a therapeutic vaccination targeting pruritus in equine

Textes supplémentaires

Abstract

This research project#s objective is to evaluate a potential benefit of blocking IL-31- mediated pruritus in allergic dermatitis of the horse. The most common allergic dermatitis of horses is the so-called insect bite hypersensitivity (IBH), an allergy against insect bites. Therefore, we will develop a therapeutic vaccine against aiming at inducing anti-IL-31 auto-antibodies. This vaccine will be compared against a monotherapy of the already existing vaccine eIL-5-VLP and a combination therapy of eIL-5-VLP and eIL-31- VLP in a placebo controlled randomized double blind phase II study. Furthermore, the vaccine production will be optimized, the clinical proof of efficacy will be obtained, and long-term safety profiles of the vaccines will be studied.

Participants

Antonia Gabriel

Wirtschaftspartner

antonia@evax.ch

Evax AG Antonia Gabriel Hörnlistrasse 3 9542 Münchwilen TG CH

Thomas Kündig

Kontaktperson

thomas.kuendig@usz.ch

USZ Universitätsspital Zürich Dermatologie Thomas Kündig Gloriastrasse 31 8091 Zürich ZH CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2017-03-31
Date de fin
2019-11-30
Coûts totaux approuvés
CHF 374584.00
Section
20 Förderbereich Life Sciences
Domaine politique NABS
Industrielle Produktivität und Technologie

Disciplines de recherche

  • T490 Biotechnology 100.0%